Back to top
more

CytomX Therapeutics, Inc. (CTMX)

(Delayed Data from NSDQ)

$7.07 USD

7.07
454,740

+0.08 (1.14%)

Updated Aug 12, 2020 04:00 PM ET

After-Market: $7.07 0.00 (0.00%) 7:57 PM ET

4-Sell of 5       4  

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.33%
2Buy17.77%
3Hold9.37%
4Sell4.88%
5Strong Sell1.79%
S&P50010.56%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

C Value A Growth A Momentum A VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Balance Sheet

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for CTMX

 

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

Fiscal Year End for CytomX Therapeutics Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Assets          
Cash & Equivalents 296 436 374 182 187
Receivables 0 0 10 2 1
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 7 9 4 4 2
Total Current Assets 303 445 389 188 190
Net Property & Equipment 7 7 4 4 3
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 2 2 3 3 3
Deposits & Other Assets 28 2 2 4 1
Total Assets 341 457 398 199 197
Liabilities & Shareholders Equity 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Notes Payable 0 0 0 0 0
Accounts Payable 4 5 4 7 5
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 30 27 16 9 5
Income Taxes Payable 0 13 0 0 0
Other Current Liabilities 51 53 41 20 6
Total Current Liabilities 86 98 61 36 16
Mortgages 0 0 0 0 0
Deferred Taxes/Income 179 225 265 84 55
Convertible Debt 0 0 0 0 0
Long-Term Debt 25 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 1 3 2 1 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 290 326 328 121 71
Shareholders Equity 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 468 446 289 255 244
Retained Earnings -417 -315 -219 -176 -117
Other Equity 0 0 0 0 -0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 51 131 70 78 126
Total Liabilities & Shareholder's Equity 341 457 398 199 197
Total Common Equity 51 131 70 78 126
Shares Outstanding 45.50 45.00 38.40 36.40 36.00
Book Value Per Share 1.12 2.91 1.82 2.16 3.50

Fiscal Year End for CytomX Therapeutics Inc falls in the month of December.

All items in Millions except Per Share data.

6/30/2020 3/31/2020 12/31/2019 9/30/2019 6/30/2019
Assets          
Cash & Equivalents NA 248 296 326 349
Receivables NA 143 0 0 10
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 9 7 9 8
Total Current Assets NA 400 303 335 367
Net Property & Equipment NA 7 7 7 7
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 2 2 2 2
Deposits & Other Assets NA 27 28 28 29
Total Assets NA 437 341 373 405
Liabilities & Shareholders Equity 6/30/2020 3/31/2020 12/31/2019 9/30/2019 6/30/2019
Notes Payable NA 0 0 0 0
Accounts Payable NA 4 4 5 5
Current Portion Long-Term Debt NA 74 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 28 30 21 22
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 51 51 52
Total Current Liabilities NA 106 86 76 79
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 237 179 188 198
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 24 25 26 26
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 1 1 1
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 367 290 290 304
Shareholders Equity 6/30/2020 3/31/2020 12/31/2019 9/30/2019 6/30/2019
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 474 468 464 459
Retained Earnings NA -405 -417 -382 -358
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 70 51 82 102
Total Liabilities & Shareholder's Equity NA 437 341 373 405
Total Common Equity 0 70 51 82 102
Shares Outstanding 45.90 45.90 45.50 45.40 45.30
Book Value Per Share 0.00 1.52 1.12 1.81 2.24